Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 252 participants.
Also called NCT05569772
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 252 participants
- Sponsor
- Registry
-
NCT05569772
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Belgium
- Registry status
- Recruiting
Technical summary
Registry record NCT05569772. Randomized; triple masking; primary purpose prevention. Start 2023-09-14 (actual); primary completion 2030-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
- Acronym
- SERENA
- Condition
- Glucose Intolerance After a Recent History of Gestational Diabetes
- Intervention (Drug)
- Semaglutide Pen Injector
- Intervention (Drug)
- Semaglutide placebo
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Collaborator
- University Hospital, Antwerp
- Collaborator
- Universitair Ziekenhuis Brussel
- Collaborator
- General Hospital Groeninge
- Collaborator
- Vitaz
- Collaborator
- Centre Hospitalier Universitaire de Liege
- Collaborator
- Erasme University Hospital
- Collaborator
- Centre Hospitalier Mouscron
- Collaborator
- Jan Yperman Ziekenhuis
- Collaborator
- AZ Turnhout
- Collaborator
- AZ Sint-Lucas Brugge
- Collaborator
- Ziekenhuis aan de Stroom
- Collaborator
- Onze Lieve Vrouw Hospital
Record details
- Record id
cardio:ct-nct05569772- Content hash
78899855f88e2109f3b5b2405b3009af2891925e55a3a46b45c80b75921b63dc